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Abstract
Mother’s milk is widely accepted as nutritious and protective to the newborn mammals by
providing not only macronutrients but also immune-defensive factors. However, the mechanisms
accounting for these benefits are not fully understood. Here we show that maternal very-low-
density-lipoprotein receptor (VLDLR) deletion in mice causes the production of defective milk
containing diminished level of platelet-activating factor acetylhydrolase (PAFAH). As a
consequence, the nursing neonates suffer from alopecia, anemia and growth retardation owing to
elevated levels of pro-inflammatory platelet-activating factors (PAFs). VLDLR deletion
significantly impairs the expression of phospholipase A2 group 7 (Pla2g7) in macrophages, which
decreases PAFAH secretion. Exogenous oral supplementation of neonates with PAFAH
effectively rescues the toxicity. These findings not only reveal a novel role of VLDLR in
suppressing inflammation by maintaining macrophage PAFAH secretion, but also identify the
maternal VLDLR as a key genetic program that ensures milk quality and protects the newborns.
Introduction
Mother’s milk protects the nursing newborns by providing immune-defensive factors1, but
how this protection is achieved is not well understood. Platelet-activating factors (PAF)
represent a class of potent pro-inflammatory lipids that are present in neonates whose
immune system is not fully developed, and is elevated in infants suffering inflammatory
disorders such as necrotizing enterocolitis (NEC)1,2. Previous studies in both human and
rodents show that milk contains the secreted form of the PAF degradation enzyme platelet-
activating factor acetylhydrolase (PAFAH), which may be critical to suppress the
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tinflammatory activity in the nursing neonates2–4. Nonetheless, how milk PAFAH level is
controlled is unknown.
VLDLR is a member of the LDL receptor family and is known to regulate triglyceride
metabolism5 and brain development6. It has been shown that activation of VLDLR by its
ligands such as Reelin (Reln)6–8 triggers downstream signaling events that modulate
neuronal functions. However, whether and how VLDLR regulates macrophage functions is
underexplored. Here we identify a novel anti-inflammatory role of VLDLR in maintaining
macrophage PAFAH secretion, and demonstrate its physiological significance in ensuring
milk PAFAH levels and protecting the nursing newborns from systemic inflammation.
Results
Maternal VLDLR deletion results in defective milk
We found that the mouse pups nursed by the Vldlr−/− mothers developed a transient alopecia
that initiated around postnatal day 16 (P16), and became prominent ~P24 (Fig. 1a), but
recovered after weaning to a standard chow diet (~P30). These pups also exhibited growth
retardation (Fig. 1b) and anemia (Fig. 1c) compared with the pups nursed by WT mothers.
These symptoms suggested a systemic toxicity that targeted the fast-proliferating cells such
as hair follicles and erythrocyte precursors. This phenotype was strictly dependent on the
maternal genotype but independent of the paternal or pup genotype because it only occurred
when the mothers were Vldlr−/− regardless of whether the fathers or pups were WT, Vldlr+/−
or Vldlr−/−. Furthermore, this phenotype was reversed by cross-fostering the pups between
Vldlr−/− and WT mothers starting P1 (Table 1 and Fig. 1d–e), indicating that it resulted from
a postnatal defect in lactation rather than a prenatal defect in gestation.
Maternal VLDLR deletion causes neonatal inflammation
The skin of the pups nursed by the Vldlr−/− mothers exhibited hyperplasia and follicular
cysts (Fig. 2a), increased leukocyte (CD11b+) infiltration (Fig. 2b), and elevated expression
of inflammatory genes including IL-1β, TNFα and COX-2 (Fig. 2c). Moreover, serum level
of the inflammatory cytokine TNFα was 4-fold higher in the pups nursed by the Vldlr−/−
mothers compared to pups nursed by WT mothers (Fig. 2d). These results indicate that the
alopecia associated with the neonatal toxicity was triggered by a systemic inflammatory
response due to the ingestion of the defective milk from the Vldlr−/− mothers.
Increased PAF levels in pups nursed by Vldlr−/− mothers
In efforts to pinpoint the biochemical mechanisms underlying the inflammation and hair
loss, we performed global metabolomic profiling9–11 using untargeted liquid
chromatography-mass spectrometry (LC-MS)12,13 to identify the metabolites that were
differentially regulated between the skin of the pups nursed by Vldlr−/− mothers and the skin
of the pups nursed by WT mothers. We found that a platelet-activating factor (PAF) was
significantly increased in the defective skin (2.6-fold) (Supplementary Fig. S1). To further
quantify PAF levels in a more specific and sensitive manner, we next performed multiple
reaction monitoring (MRM) LC-MS/MS analysis using deuterium-labeled standards as
internal controls. The results showed that both PAF-C16 and PAF-C18 were significantly
elevated in the skin (Fig. 3a) and the intestine (Fig. 3b) of the pups nursed by Vldlr−/−
mothers compared to the pups nursed by WT mothers.
PAFAH secretion in Vldlr−/− milk is decreased
We next performed ELISA analysis to compare PAFAH activity in the milk. The result
demonstrated that PAFAH activity was significantly lower in the milk from Vldlr−/−
mothers than in the milk from WT mothers (Fig. 3c). Consistent with this finding, PAFAH
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tactivity in the plasma of the pups nursed by Vldlr−/− mothers was also significantly reduced
compared with the pups nursed by WT mothers (Fig. 3d). By contrast, the expression of
PAF synthases (Lpcat1 and Lpcat2) was unaltered in the skin and intestine of the pups
nursed by Vldlr−/− mothers (Supplementary Fig. S2). This finding suggests that the elevated
PAF was caused by decreased degradation by PAFAH rather than increased PAF synthesis.
In line with these observations, plasma PAFAH activity was comparable between neonatal
Vldlr−/− pups and WT littermate control pups when nursed by the same Vldlr+/−
heterozygous mother (Supplementary Fig. S3a), further confirming that neonatal PAFAH is
maternal-genotype-dependent and predominantly from milk. After weaning, plasma PAFAH
activity was significantly lower in adult Vldlr−/− mice compared with WT controls
(Supplementary Fig. S3b), indicating that adult PAFAH is offspring/self-genotype-
dependent. Nonetheless, adult Vldlr−/− mice did not develop alopecia and their serum TNFα
level was unaltered (unpublished observation, YW), indicating that inflammation only
occurs during nursing, possibly due to the milk fat intake and the immature gut epithelium/
immune system/hair follicle in the neonates.
Because PAFAH in the milk is mainly secreted from macrophages3, we next compared
PAFAH activity in the culture medium of macrophages differentiated from bone marrow
cells or splenocytes. The results showed that Vldlr−/− bone marrow-derived macrophages
secreted 44% less PAFAH, and Vldlr−/− splenocyte-derived macrophages secreted 54% less
PAFAH compared to WT macrophages (Fig. 3e).
Decreased Pla2g7 expression in Vldlr−/− macrophage
Because the secreted form of PAFAH is encoded by the Pla2g7 gene14, we next asked
whether the diminished PAFAH secretion from Vldlr−/− macrophages was due to reduced
Pla2g7 expression. The results showed that comparing to WT macrophages, Pla2g7 mRNA
levels were 53% and 80% lower in Vldlr−/− macrophages differentiated from bone marrow
or splenocyte, respectively (Fig. 4a). By contrast, macrophage expression of PAF synthases
(Fig. 4b) or lipoproteins (Supplementary Fig. S4) were unaltered. FACS analysis of bone
marrow and peripheral blood shows that the percentage of macrophages (CD11b+) was
similar between adult Vldlr−/− and WT mice (Fig. 4c), indicating that macrophage
maturation was unaffected by VLDLR deletion.
Consistent with these observations, results from the next three experiments further confirm
VLDLR regulation of Pla2g7 mRNA expression in macrophage. First, mRNA of Vldlr and
Pla2g7 were concurrently increased during a differentiation time course of WT macrophages
(Fig. 4d). Second, VLDLR knockdown by siRNA also significantly decreased Pla2g7
expression in the human monocyte THP-1-derived macrophages (Fig. 4e). Third, exogenous
VLDLR expression rescued Pla2g7 expression in Vldlr−/− bone marrow macrophages (Fig.
4f). Together these findings indicate that VLDLR is required for normal Pla2g7 expression
in macrophages, and VLDLR deletion reduces PAFAH secretion in the milk.
Regulation of Pla2g7 by VLDLR is mediated by Reln and Dab2
We next explored the ligand and signaling pathway that mediate the VLDLR regulation of
Pla2g7 expression in macrophage. Reelin (Reln) is a VLDLR ligand6–8 expressed in several
cell types in the mammary gland, including epithelium and stroma15,16. We found that Reln
was also expressed in macrophages (unpublished observation, YW), suggesting an autocrine
regulation of VLDLR signaling. Thus, we compared Pla2g7 expression in Reln−/− and WT
macrophages that were differentiated from the bone marrow of 20-day-old (before lethality)
reeler mice8 or WT littermate controls. The result shows that Pla2g7 expression was
significantly reduced by 38% in the Reln−/− macrophages (Fig. 4g), indicating that Reln is a
functional VLDLR ligand in the regulation of Pla2g7.
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to transmit lipoprotein receptor signaling17–19. We found that macrophages expressed
specifically Dab2, but not Dab1 (unpublished observation, YW). Thus, we examined the
effect of siRNA-mediated Dab2 knockdown on Pla2g7 expression in bone marrow
macrophages. The result showed that Pla2g7 expression was significantly reduced by 68%
in the Dab2-deficient macrophages (Fig. 4h), indicating that Dab2 is an important mediator
of VLDLR signaling for the regulation of Pla2g7. Based on these evidences, we propose a
working model that activation of macrophage VLDLR by ligands such as Reln triggers
Dab2-mediated signaling transduction to promote Pla2g7 expression (Fig. 5).
PAFAH feeding to the pups rescues the neonatal toxicity
To further investigate whether the inflammation and toxicity in the pups nursed by the
Vldlr−/− mothers was caused by the insufficient levels of PAFAH in the milk, we tested
whether the alopecia phenotype could be rescued by exogenous PAFAH supplementation to
the pups. Pups from the same Vldlr−/− mother were divided into two groups: the first group
was orally gavaged with recombinant human PAFAH (0.15mg/kg/day) starting P1, and the
second group was gavaged with vehicle (PBS) as controls. The results demonstrated that
hair loss occurred in all the PBS-treated control pups but was completely prevented in all the
PAFAH-treated pups (Fig. 6a). Consistent with this observation, the excessive leukocyte
infiltration (Fig. 6b), inflammatory gene expression (Fig. 6c) and PAF accumulation (Fig.
6d) in the control pups were significantly attenuated in the PAFAH-treated pups.
To quantify PAFAH protein in pup serum, we performed western blot analyses using two
antibodies, sc-23021 (G-18) and sc-23022 (E-15). Although both antibodies recognized
endogenous human and mouse PAFAH, only E-15, but not G-18, recognized the
recombinant human PAFAH (Fig. 6e, left). This allowed us to specifically quantify
rhPAFAH using the signal ratio of E15/G18 (total/endogenous PAFAH). The results show
that the PAFAH-gavaged pups had a 2.2-fold higher total PAFAH serum level than the PBS-
gavaged littermate controls (Fig. 6e, middle and right). This indicates that milk-borne
PAFAH can be transmitted to the circulation of the nursing neonates.
Furthermore, supplementation of WT milk with a non-hydrolyzable PAF analog (c-PAF or
carbamyl-PAF)20 was sufficient to induce neonatal alopecia (Supplementary Fig. S5a); and
supplementation of Vldlr−/− milk with a PAF receptor antagonist (WEB-2086 or apafant)21
also effectively rescued neonatal alopecia (Supplementary Fig. S5b). Together these results
provide compelling evidence that maternal VLDLR deletion diminishes milk PAFAH level,
thereby causing PAF accumulation in the nursing pups, which leads to neonatal
inflammation and toxicity.
Discussion
Our findings not only reveal a novel anti-inflammatory role of VLDLR in maintaining
macrophage Pla2g7 expression and PAFAH secretion, but also demonstrate its physiological
significance in ensuring milk quality and protecting the nursing newborns. First, these
studies reveal that maternal PAFAH in the milk is transmitted to the nursing neonates and
plays a crucial role in their development by preventing excessive inflammation. Thus, our
findings have identified PAFAH as a novel and critical immune-defensive factor in the milk.
Second, studies from human and rodents show that mutations or dysregulation of VLDLR
are often associated with dementia, cerebellar ataxia, mental retardation or
dyslipidemia22–29. The novel regulation of PAFAH and inflammation by VLDLR may
provide new insights to these human diseases. Third, despite the widely reported anti-
inflammatory or sometimes pro-inflammatory roles of PAFAH in various physio-
pathological contexts2,14,30–35, the mechanisms underlying the regulation of Pla2g7
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texpression are unknown; in particular, a functional control of PAFAH by a lipoprotein
receptor has never been demonstrated or hypothesized. Hence, the novel finding that
VLDLR promotes macrophage PAFAH production may have broad implications in the
etiology and treatment of neonatal disorders that are associated with inflammation such as
NEC2–4 and atopic dermatitis36, as well as inflammatory diseases in adulthood that are
associated with PAF and PAFAH such as Crohn’s disease31, atherosclerosis33,35,
asthma32,34 and macular degeneration37,38.
Methods
Mice
Vldlr−/− mice39 were purchased from Jackson Laboratory and backcrossed to C57BL/6 for
at least 3 generations. Reeler mice8 were purchased from Jackson Laboratory. For milk and
pup analyses, 8–16 weeks old female Vldlr−/− mice or WT control mice were bred to WT
male mice. The litter sizes were normalized to six pups. Mice were fed standard rodent chow
ad libitum. Milk was collected as described13. On lactation day 8–12, lactating females were
separated from their pups for 3–5 h to allow the mammary glands to refill. Before milking,
the lactating female was anesthetized with an i.p. injection of avertin (0.6 mL of a 20 mg/mL
stock), and then i.p. injected with 0.5 U of oxytocin (0.2 mL of a 2.5 U/mL stock) to induce
milk ejection. Milk was immediately collected from mammary glands by gentle vacuum
suction through a capillary tube. All 10 mammary glands were milked two rounds for a total
of 20 min per mouse, allowing the collection of most of the milk. All protocols for mouse
experiments were approved by the Institutional Animal Care and Use Committee of
University of Texas Southwestern Medical Center.
Reagents
Immuno-fluorescence staining was performed using FITC-anti-CD11b or FITC-isotype-
control (1:200) (BD Biosciences). Serum TNFα was measured using a Cytometric Bead
Array Mouse Inflammation Kit (BD Biosciences). CBC was performed at Antech
Diagnostics. All mRNA expression was measured by RT-QPCR (SYBR Green) in triplicate
and normalized by L19 (for mouse) or 36B4 (for human). PAFAH activity was measured by
an ELISA kit (Cayman Chemical). For PAFAH rescue experiment, recombinant PAFAH
(Antigenix America) was dissolve in PBS and orally gavaged at 0.15 mg/kg/day starting P1.
Anti-PAFAH antibodies (1:500), siRNAs, c-PAF and WEB-2086 were from Santa Cruz
Biotechnology.
Macrophage Differentiation
For macrophage differentiation, bone marrow cells or splenocytes were isolated from
Vldlr−/− mice or WT mice, and cultured in α-MEM containing 10% FBS and 20ng/ml M-
CSF for 12 days with a change of medium every 4 days. On day 12, culture medium was
collected for PAFAH activity assay, RNA was collected from the cells for RT-QPCR
analysis. THP-1 cells were transfected with hVLDLR siRNA or control siRNA (Santa Cruz
Biotechnology) with Lipofectamine RNAiMAX transfection reagent (Life Technologies),
and differentiated 24 h later with 40 ng/ml TPA for 2 days17.
Lipid Analysis by Mass Spectrometry
For global metabolomic profiling, organic soluble metabolites were extracted from 0.1g of
tissue, subjected to untargeted analysis using an Agilent Accurate-Mass TOF LC-MS
instrument under positive and negative ionization mode, and data were analyzed using
XCMS software for peak alignment and quantification12,13. For PAF LC-MS/MS analysis,
d4-PAF-C16 and d4-PAF-C18 standards (Cayman Chemical) were added to each tissue
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tsample at 1 pmol/mg before lipid extraction. A Gemini C18 column (Phenomenex) was used
for a reverse phase separation of the lipids, with mobile phase A as 0.1% formic acid v/v,
and mobile phase B as 100% acetonitrile, 0.1% formic acid v/v. A gradient elution from 5%
B to 100% B was done over 20 minutes, and held at 100% B for 5 minutes before a 13
minute re-equilibration. MS/MS quantification of PAF-C16, d4-PAF-C16, PAF-C18, d4-
PAF-C18 was performed on an Agilent 6410 triple quadrupole mass spectrometer in
multiple reaction monitoring (MRM) mode using electrospray ionization in positive ion
mode. All of these compounds readily fragmented upon activation to a choline ion at m/
z=184. An optimum fragmentor voltage of 170 V and collision energy of 24 eV was
determined and the following transitions were monitored: PAF-C16 (524.5→184), d4-PAF-
C16 (528.5→184), PAF-C18 (552.5→184), d4-PAF-C18 (556.5→184). Integrated peak
area for these transitions was used for quantification. The level of each endogenous PAF
was normalized by the corresponding deuterium-labeled internal control.
Statistical Analyses
Statistical analyses were performed with Student’s t-Test and represented as mean ±
standard deviation (s.d.); *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001; n.s., non-
significant.
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tFigure 1. Maternal VLDLR deletion causes neonatal toxicity due to lactation defects
a–c, Nursing pups from Vldlr−/− mothers exhibited alopecia, growth retardation and anemia
compared with pups from WT control mothers. WT or Vldlr−/− female mice were bred with
WT male mice, and the pups (WT or Vldlr+/−, respectively) were analyzed at postnatal day
24 (P24) (n=12 from 2 independent litters). a, A representative image of the hair loss. b, Pup
body weight. c, Complete blood cell count (CBC) of the pups. RBC, red blood cell; HGB,
hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration. d–e, Cross-fostering reversed the growth retardation and anemia in the pups
(n=2 independent fostering pairs). WT or Vldlr−/− (KO) female mice were bred with WT
male mice. On P1, three pups were switched between the KO mother (Vldlr+/− pups) and
the WT mother (WT pups), and three pups were left with the original mother as controls.
The fostered pups and the original pups were distinguished by ear punch and analyzed at
P24. d, Pup body weight. e, CBC of the pups. B, birth/gestation mother; F, foster/lactation
mother; KO, Vldlr−/−. Statistical analyses were performed with Student’s t-Test and all data
are shown as mean ± standard deviation; *, p<0.05; **, p<0.01; ***, p<0.005; ****,
p<0.001.
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tFigure 2. Maternal VLDLR deletion causes neonatal inflammation
a–c, Defects in the skin of the pups nursed by Vldlr−/− mothers compared with the pups
nursed by WT control mothers. a, H&E staining showed skin hyperplasia and follicular
cysts (FC, indicated by arrows). Scale bars, 100μm. b, Immuno-fluorescence staining
showed leukocyte infiltration in the skin at P19. Skin sections were stained with a FITC-
CD11b antibody or FITC-isotype control (to show non-specific staining of the hair shafts).
Scale bars, 100μm. c, RT-QPCR analysis showed increased inflammatory gene expression
in the skin (n=3). d, Serum level of TNFα was elevated in the pups nursed by Vldlr−/−
mothers compared to the pups nursed by WT control mothers (n=12, P19). The pups nursed
by Vldlr−/− mothers were Vldlr+/−, and the pups nursed by WT mothers were WT.
Statistical analyses were performed with Student’s t-Test and are shown as mean ± standard
deviation; *, p<0.05; ***, p<0.005; ****, p<0.001; n.s., non-significant.
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tFigure 3. Maternal VLDLR deletion elevates PAFs in pups and diminishes PAFAH in milk
a–b, PAF levels were increased in the skin (a) and intestine (b) of the pups nursed by
Vldlr−/−mothers compared to the pups nursed by WT control mothers. Tissue lipids were
analyzed by MRM LC-MS/MS to quantify PAF-C16 (left) and PAF-C18 (right) levels
(n=3). The results were normalized to d4-PAF-C16 or d4-PAF-C18 internal control,
respectively. P, postnatal day. c, PAFAH activity was decreased in the milk of Vldlr−/−
mothers compared to WT mothers (n=4). d, PAFAH activity was decreased in the plasma of
the pups nursed by Vldlr−/− mothers compared to the pups nursed by WT mothers (n=8). For
a, b, d, the pups nursed by Vldlr−/− mothers were Vldlr+/−, and the pups nursed by WT
mothers were WT. e, PAFAH activity was decreased in the culture medium of Vldlr−/−
macrophages compared to WT macrophages that were differentiated from bone marrow
(BM) or splenocyte (Sp) (n=4). For e, 1×106 macrophages were differentiated from 1.5×106
bone marrow cells or 5×106 splenocytes of Vldlr−/− mice or WT control mice (male, 3
month old). PAFAH activity was normalized to macrophage cell number (×106). Statistical
analyses were performed with Student’s t-Test and all data are shown as mean ± standard
deviation; **, p<0.01; ***, p<0.005; ****, p<0.001.
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tFigure 4. Macrophage VLDLR signaling promotes Pla2g7 expression
a, Pla2g7 mRNA expression was reduced in Vldlr−/− macrophages compared to WT
macrophages (n=4). BM, bone marrow; Sp, spleen. b, The mRNA expression of PAF
synthases, Lpcat1 and Lpcat2, was unaltered in the Vldlr−/− BM macrophages (BM, n=4).
For a–b, 1×106 macrophages were differentiated from 1.5×106 bone marrow cells or 5×106
splenocytes of Vldlr−/− mice or WT control mice (male, 3 month old). c, FACS analysis of
macrophages (CD11b+) in the bone marrow (BM) and peripheral blood (PB) of Vldlr−/−
mice and WT control mice (n=3, male, 3 month old). d, Pla2g7 and Vldlr mRNA levels
during a differentiation time course of WT bone marrow macrophages (n=4, male, 3 month
old). The p values compare the expression on day 8 (d8) or day 12 (d12) with the expression
on day 4 (d4). e, VLDLR knock-down decreases Pla2g7 mRNA expression in human
macrophages (n=3). The human monocyte cell line THP-1 was transfected with hVLDLR
siRNA (si-VLDLR) or control siRNA (si-Ctrl) for 24 hrs, and then differentiated into
macrophage with TPA (40 ng/ml) for 48hrs. f, Exogenous VLDLR expression rescues
Pla2g7 mRNA expression in Vldlr−/− macrophages (n=3). Bone marrow cells from Vldlr−/−
mice (male, 3 month old) were transfected with VLDLR or vector control for 24 h, and
differentiated into macrophage with MCSF for 6 days. g, Pla2g7 mRNA expression was
reduced in Reln−/− macrophages (n=4). Macrophages were differentiated from the bone
marrow of 20-day-old Reln−/− (reeler) or WT littermate control mice before the lethality of
reeler mice at ~6 week. h, Pla2g7 mRNA expression was reduced in Dab2-deficient
macrophages (n=3). WT bone marrow cells were transfected with Dab2 siRNA (si-Dab2) or
control siRNA (si-Ctrl) for 24 hrs, and then differentiated into macrophages. Statistical
analyses were performed with Student’s t-Test and all data are shown as mean ± standard
deviation; *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001; n.s., non-significant.
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tFigure 5. Reln-VLDLR-Dab2 signaling pathway in macrophages regulates Pla2g7 expression
According to our working model, activation of macrophage VLDLR by ligands such as Reln
triggers Dab2-mediated signaling transduction to promote Pla2g7 expression.
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tFigure 6. Oral PAFAH supplementation to the pups rescues the neonatal toxicity
Pups from a Vldlr−/− mother were orally gavaged with recombinant PAFAH at 0.15 mg/kg/
day starting P1 (n=3); as internal controls, pups in the same litter were gavaged with vehicle
PBS (n=3). The pups were analyzed at P21. a, A representative image showing the rescue of
pup hair loss by PAFAH. b, Immuno-fluorescence staining showing the reduction of
leukocytes (CD11b+) in the pup skin by PAFAH. Scale bars, 100μm. c, RT-QPCR analysis
showing the attenuated expression of inflammatory genes in the pup skin by PAFAH (n=3).
d, LC-MS/MS analysis showing the reduced levels of PAF-C16 (left) and PAF-C18 (right)
in the intestine and skin of the PAFAH-treated pups (n=3). e, Western blot analyses of
PAFAH protein. Left: comparison of two anti-PAFAH antibodies. Representative result of
two independent experiments is shown. The abbreviations are: CM, conditioned medium; m,
mouse; h, human; r, recombinant; BMM, bone marrow macrophage. Middle: western blot
image for the detection of endogenous (top) and total (bottom) PAFAH in the serum of pups
gavaged with PAFAH or PBS control. Right: quantification of the ratio of total/endogenous
PAFAH protein in pup serum (n=2). Statistical analyses were performed with Student’s t-
Test and all data are shown as mean ± standard deviation; *, p<0.05; **, p<0.01; ***,
p<0.005.
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Table 1
Cross-fostering reversed the alopecia in the pups
Birth/Gestation Mom Foster/Lactation Mom Hair Loss (% Pup) (n=10–12) Hair Loss (% Litter) (n=4)
WT WT 0 0
Vldlr−/− Vldlr−/− 100 100
Vldlr−/− WT 0 0
WT Vldlr−/− 80 100
WT, wild type.
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